Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A phase 1/2 trial of Olomorasib, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) is a phase 1/2 interventional study registered as NCT04956640 by Eli Lilly and Company, with 540 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2027-04. Interventions recorded: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Olomorasib, Eli Lilly (incl. Loxo), Pemetrexed, Cisplatin and the tag pipeline.
- TrialA Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Shares Cetuximab, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Pemetrexed, Cisplatin, Merck & Co. (MSD), Carboplatin and the tag pipeline.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Cisplatin, Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Pemetrexed, Cisplatin, Merck & Co. (MSD), Carboplatin and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Shares Cisplatin, Endometrial cancer, Merck & Co. (MSD), Carboplatin and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Shares Cisplatin, Endometrial cancer, Merck & Co. (MSD), Carboplatin and the tag pipeline.